Stephen Mark Tompkins

US Patent:

8278083, Oct 2, 2012

Filed:

Mar 23, 2007

Appl. No.:

12/225551

Inventors:

Yossef Raviv - Rockville MD, US
Mathias Viard - Frederick MD, US
Robert Blumenthal - Bethesda MD, US
Robert J. Hogan - Athens GA, US
Stephen Mark Tompkins - Watkinsville GA, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
University of Georgia Research Foundation, Inc. - Athens GA

International Classification:

A61K 39/145
C12N 13/00

US Classification:

4351733, 4242091, 4242351

Abstract:

The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza.

US Patent:

20100204300, Aug 12, 2010

Filed:

Jan 16, 2008

Appl. No.:

12/522456

Inventors:

Stephen Mark Tompkins - Watkinsville GA, US
Jeffrey Robert Hogan - Athens GA, US

International Classification:

A61K 31/7105
C07H 21/02
C12N 15/74
C12N 5/10
A61P 31/12

US Classification:

514 44 A, 536 245, 4353201, 435325

Abstract:

The instant disclosure relates to methods and compositions for silencing poxvirus gene expression and replication using RNA interference. In certain embodiments, the disclosure relates to methods of treating a subject with a poxvirus infection.

US Patent:

20180273908, Sep 27, 2018

Filed:

Jul 6, 2016

Appl. No.:

15/742766

Inventors:

- Athens GA, US
Stephen M. Tompkins - Watkinsville GA, US

International Classification:

C12N 7/00
C12N 5/071
C12N 15/113

Abstract:

Disclosed are compositions and methods for increasing influenza virus production.

US Patent:

20170151322, Jun 1, 2017

Filed:

Feb 5, 2014

Appl. No.:

14/765365

Inventors:

- Athens GA, US
- Bethesda MD, US
- Waltham MA, US
Stephen M. Tompkins - Watkinsville GA, US

International Classification:

A61K 39/13
C12N 7/00
C12N 15/113

Abstract:

Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.

US Patent:

20140121237, May 1, 2014

Filed:

Oct 14, 2013

Appl. No.:

14/052998

Inventors:

- ATHENS GA, US
STEPHEN M. TOMPKINS - WATKINSVILLE GA, US

International Classification:

A61K 31/195
A61K 31/18
A61K 45/06
A61K 31/122

US Classification:

514301, 514562

Abstract:

The present invention provides methods for treating a subject having, or at risk of having, a viral infection. The methods include, but are not limited to, the use of 4-(dipropylsulfamoyl)benzoic acid, an inhibitor of CDC25B phosphatase, an inhibitor of ICAM-1, an inhibitor of CamK2B, or a combination thereof.